Sugi Predict

Sugi Predict / Compounds / SCHEMBL263475

SCHEMBL263475

SCHEMBL263475

COc1ccc(OC(F)(F)F)c(B(O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 3/20 0.43
▸ TUBB P07437 3/20 0.43
▸ TUBA3C P0DPH7 3/20 0.43
▸ TUBA1B P68363 3/20 0.43
▸ TUBA4A P68366 3/20 0.43
▸ TUBB4B P68371 3/20 0.43
▸ TUBB3 Q13509 3/20 0.43
▸ TUBB2A Q13885 3/20 0.43
▸ TUBB8 Q3ZCM7 3/20 0.43
▸ TUBA3E Q6PEY2 3/20 0.43
▸ TUBA1A Q71U36 3/20 0.43
▸ TUBA1C Q9BQE3 3/20 0.43
▸ TUBB6 Q9BUF5 3/20 0.43
▸ TUBB2B Q9BVA1 3/20 0.43
▸ TUBB1 Q9H4B7 3/20 0.43
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956393 0.86 TUBB4A (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL320667 0.86 TUBB4A (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL17157371 0.86 CA1 (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29953466 0.86 CA1 (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL262886 0.82 L3MBTL1 (0.44) NPC1MAPTALDH1A1MEN1KMT2A
SCHEMBL518510 0.81 TUBB4A (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29385414 0.81 TUBB4A (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5051598 0.80 TUBB4A (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24436846 0.79 ALDH1A1 (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15269928 0.79 PDE2A (0.36) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 — — CN disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 — — EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 — — US disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 — — US disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 — — US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 — — EP disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 — — US disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 — — US disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 — — US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 — — WO disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS TUBB4A 4447/4885TUBB 3670/4885TUBA3C 4527/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS TUBB4A 4534/4885TUBB 4122/4885TUBA3C 4735/4885
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 TUBB4A 1093/4885TUBB 1131/4885TUBA3C 1096/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS TUBB4A 4343/4885TUBB 3441/4885TUBA3C 4512/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS TUBB4A 4319/4885TUBB 3404/4885TUBA3C 4491/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS TUBB4A 4447/4885TUBB 3670/4885TUBA3C 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.